Drug development for Alzheimer’s disease has been a series of disappointments, with only faint glimmers of hope from pharmaceutical companies or academic labs. What causes the disease is still hotly debated, with the amyloid hypothesis losing believers after each new trial failure.

But before those drugs targeting amyloid plaques or tau tangles failed in human trials, they generally succeeded in preclinical studies — specifically, ones done with mice. Right now, about 160 mouse models for Alzheimer’s exist. But none is particularly good, experts say.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Too bad the public is so misinformed that they have no idea that mouse trials rarely represent humans. This is an Advertorial written to stimulate funding for these failed scientific dead ends. there is no mouse model for any type of Dementia, yet selling it as if there is can be profitable. Dementia an be misdiagnosed for years by Physicians. Soon it will be a leading cause of death. The Medical Industry refuses to diagnose or even acknowledge these conditions until it is much to late.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy